BrainCheck, a digital platform for cognitive assessment and care, today announced that it has raised an additional $13 million in Series A financing. The round was led by Next Coast Ventures, with participation from S3 Ventures and UPMC Enterprises.

The funding will support the expansion of BrainCheck’s enterprise cognitive care infrastructure, including deeper workflow integration, longitudinal patient monitoring, population-scale deployment across primary care and specialty settings, and advanced AI-assisted clinical infrastructure designed for risk-bearing and value-based environments.

In addition to technology expansion, BrainCheck is now partnering with collaborative care organizations to operationalize cognitive care delivery within practices that lack the staffing or infrastructure to execute comprehensive care workflows. These partnerships extend BrainCheck beyond assessment into structured, scalable cognitive care pathways—supporting providers with both digital tools and operational care enablement models.

As populations age and accountability for cognitive outcomes shifts toward value-based and risk-bearing models, standardized cognitive assessment is increasingly serving as the entry point to new care pathways. BrainCheck’s platform is designed to help practices identify cognitive impairment earlier and activate structured follow-up care in a sustainable, scalable manner.

“Cognitive health is becoming a greater priority across the healthcare system, and the infrastructure supporting it must evolve as well,” said Mike Smerklo, Co-Founder and Managing Partner of Next Coast Ventures. “BrainCheck is contributing to that evolution by bringing greater consistency, objectivity, and longitudinal insight into cognitive care. We’re excited to support the company’s next phase of growth.”

“UPMC clinicians have been evaluating BrainCheck for several years and have seen firsthand how standardized digital cognitive assessment can support them in real-world practice,” said Adele Towers, M.D., M.P.H., UPMC geriatrician and senior clinical advisor to UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC. “We look forward to our continued engagement with BrainCheck and bringing it to more clinicians supporting patients who could benefit from earlier detection, long-term monitoring, and scalable cognitive care within and beyond our health system.”

BrainCheck is used by more than 500 healthcare organizations nationwide, with clinicians having completed over 640,000 cognitive assessments using BrainCheck Assess™, the company’s FDA Class II digital cognitive assessment (DCA). The BrainCheck platform offers 29 validated cognitive screeners and care planning tools designed to enable standardized, repeatable measurement and longitudinal tracking, fully integrated into clinical workflows.

Testing protocols are customizable within the BrainCheck platform and available in English and Spanish. Providers across primary care, neurology, and psychiatry use the platform to assess and monitor cognitive function and behavioral changes across a range of neurological and psychiatric conditions, with a primary focus on mild cognitive impairment (MCI) and dementia-related diseases, including Alzheimer’s disease.

BrainCheck’s strategy centers on building structured cognitive care pathways that support:

• Earlier identification of cognitive risk
• Objective, repeatable assessment over time
• AI-assisted population health and longitudinal analysis
• Seamless integration into health system environments and EHR systems
• Coordination across clinical teams and care settings

The platform is designed to reduce operational friction within time-constrained clinical environments while ensuring that interpretation and care decisions remain fully clinician-directed.

“This capital allows us to continue building tools and workflows that fit how clinicians actually practice,” said Chris Loughlin, Chief Executive Officer of BrainCheck. “We are focused on reducing friction in cognitive assessment, supporting longitudinal care, and using AI responsibly to assist, never replace, clinical decision-making.”

As the population ages, the gap between cognitive impairment and formal diagnosis continues to widen. Primary care clinicians lack the time, staffing, and infrastructure to manage cognitive health longitudinally, even as demand accelerates.

At the same time, blood-based biomarkers and emerging therapies are transforming the care pathway. Objective digital cognitive assessment is increasingly becoming the starting point of this new continuum—guiding risk stratification, informing laboratory and specialty referral, and enabling structured follow-up.

BrainCheck provides a standardized digital infrastructure designed to support this transformation at a population scale across large health systems and accountable care organizations. By embedding repeatable cognitive measurement directly into clinical workflows, the platform helps practices and ACOs close the diagnosis gap, activate appropriate care pathways, and scale modern cognitive care across large patient populations.

“Physicians have limited time to address cognitive care,” said Stephen Bekanich, M.D., Chief Medical Officer of BrainCheck. “Accountable Care Organizations and value-based care models are increasingly responsible for identifying cognitive impairment earlier and managing it longitudinally across large patient populations. We are seeing the emergence of collaborative care structures designed to support that accountability. BrainCheck provides the standardized, scalable infrastructure that enables these models to operate effectively.”

For more information, visit www.braincheck.com.

About BrainCheck

BrainCheck is a clinically validated digital platform for cognitive assessment and care, anchored by BrainCheck Assess™—its flagship FDA Class II digital cognitive assessment. The platform delivers standardized, repeatable cognitive data across clinical and research settings.

BrainCheck is used by more than 500 healthcare organizations nationwide, including Bon Secours, UPMC, and Springfield Clinic, as well as 46 research hospitals, including The University of Texas at Austin and Stanford University. Clinicians use BrainCheck’s validated screeners and care planning tools to build tailored protocols, with more than 640,000 cognitive assessments and 14,000 Care Plans completed to date.

BrainCheck is intended to support clinical decision-making and is not designed to function as a stand-alone diagnostic tool.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226481557/en/

“BrainCheck is contributing to that evolution by bringing greater consistency, objectivity, and longitudinal insight into cognitive care." — Mike Smerklo, Co-Founder and Managing Partner of Next Coast Ventures